Table 1 Baseline characteristics data
|  | Danlou tablets (n = 44) | Placebo (n = 44) | P |
|---|---|---|---|
Age, yr | 67.54 ± 8.39 | 68.38 ± 10.41 | 0.18 |
Male sex, no. (%) | 28 (63.64) | 27 (61.36) | 0.83 |
BMI, kg/m2 | 22.29 ± 4.78 | 23.99 ± 3.12 | 0.35 |
Heart rate (beats/min) | 75.41 ± 13.69 | 78.84 ± 13.36 | 0.57 |
Systolic blood pressure (mmHg) | 126.44 ± 26.43 | 123.42 ± 27.18 | 0.85 |
Concomitant diseases, no. (%) | Â | ||
 Previous coronary heart disease | 12 (27.27) | 15 (34.09) | 0.49 |
 Systemic hypertension | 21 (47.73) | 23 (52.27) | 0.67 |
 Diabetes mellitus | 9 (20.45) | 10 (22.73) | 0.80 |
 Dyslipidemia | 12 (27.27) | 18 (40.91) | 0.18 |
Current smoker, no.(%) | 14 (31.82) | 12 (27.27) | 0.64 |
NYHA Class | Â | ||
 Class I | 4 (9.09) | 5 (11.36) | 0.99 |
 Class II | 20 (45.46) | 19 (43.18) | |
 Class III | 18 (40.91) | 17 (38.64) | |
 Class IV | 2 (4.54) | 3 (6.82) | |
Procedural Features | Â | ||
 LAD (%) | 35 (79.55) | 32 (72.73) | 0.45 |
 Multivessel disease (%) | 14 (31.82) | 19 (43.18) | 0.39 |
 Procedural success (%) | 44 (100) | 44 (100) | 1.00 |
 Stenting of IRA (%) | 44 (100) | 44 (100) | 1.00 |
 Multiple stenting (%) | 10 (22.73) | 8 (18.18) | 0.60 |
 Total length of stenting (mm) | 20.52 ± 7.01 | 22.37 ± 6.46 | 0.22 |
 TIMI flow grade 3 after PCI (%) | 44 (100) | 44 (100) | 1.00 |
 Procedural time (min) | 62.68 ± 19.72 | 65.32 ± 19.55 | 0.51 |
Cardiac biomarker | Â | ||
 Peak CK-MB (IU/L) | 68.01 [46.83–99.90] | 64.34 [19.65–97.98] | 0.21 |
 NT-proBNP (pg/mL) | 1419.27 [293.41–2678.54] | 1147.21 [240.50–2675.61] | 0.55 |
Therapy, no. (%) | Â | ||
 Aspirin | 42 (95.45) | 43 (97.73) | 0.56 |
 Clopidogrel | 44 (100) | 44 (100) | 1.00 |
 Statin | 44 (100) | 44 (100) | 1.00 |
 Beta adrenergic blockers | 40 (90.91) | 41 (93.18) | 0.69 |
 ACE inhibitors (or ARB) | 41 (93.18) | 42 (95.45) | 0.65 |
 Aldosterone antagonist | 5 (11.36) | 4 (9.09) | 0.73 |
 Digitalis | 8 (18.18) | 6 (13.64) | 0.56 |